Table 2.

Disease characteristics of the patients with PsA at baseline

Variable	Patients n = 41
PsA peripheral arthritis, n (%)	35 (85.4)
PsA axial disease, n (%)	2 (4.9)
PsA peripheral and axial combination, n (%)	4 (9.7)
Disease duration, years	17 (11; 27)
DAPSA, score	15.3 (6.6; 29.0)
DAS28-CRP, score	2.9 (2.1; 3.7)
CRP, mg/l	4.0 (2.0; 8.5)
Tender joints 68, count	4.0 (0; 4.0)
Swollen joints 66, count	0.0 (0; 1.0)
LEEDS-index, count	1.0 (0; 4.0)
General health VAS, 0–100	34.0 (19.0; 61.0)
Global pain VAS, 0–100	30.0 (18.5; 62.5)
Global fatigue VAS, 0–100	25.0 (8.0; 44.0)
Pharmacological treatment
NSAIDs, n (%)	27 (65.9)
TNFi in monotherapy, n (%)	4 (9.8)
TNFi + csDMARD, n (%)	11 (26.8)
Ustekinumab in monotherapy n (%)	1 (2.4)
csDMARD in monotherapy, n (%)	19 (46.3)
Prednisolone, n (%)	2 (4.9)

For categorical variables, number (percentage) is presented. For continuous variables, median (IQR) per participant is presented. VAS, visual analog scale; bDMARD, biologic disease modifying anti-rheumatic drug; csDMARD, conventional synthetic disease modifying anti-rheumatic drug; NSAID, nonsteroidal anti-inflammatory drug; TNFi, tumor necrosis factor inhibitor